Belsomra Liver Function Impact: What Suvorexant Does (and Doesn't Do) to Hepatic Health

How Suvorexant Is Processed by the Liver

Suvorexant is extensively metabolized by the liver before elimination. Understanding that pathway is the starting point for any conversation about hepatic risk.

The drug is a substrate of CYP3A4, the cytochrome P450 isoenzyme responsible for metabolizing roughly 50 percent of clinically used drugs. CYP2C19 contributes a minor secondary pathway. After oral dosing, suvorexant undergoes first-pass hepatic metabolism to a hydroxylated metabolite that is largely inactive. The parent compound reaches peak plasma concentration (Tmax) in approximately 2 hours under fasting conditions, a figure that extends to roughly 3 hours with a high-fat meal. The FDA prescribing information confirms an oral bioavailability of approximately 82 percent at the 20 mg dose.

CYP3A4 as the Rate-Limiting Step

Because CYP3A4 sits inside hepatocytes, any condition that reduces functional liver mass or enzymatic activity will slow suvorexant clearance. This is the mechanistic reason that hepatic impairment matters for dosing, not because suvorexant is chemically toxic to liver cells.

Strong CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir) can double suvorexant area under the curve (AUC). The FDA label specifies that the recommended dose with a moderate CYP3A4 inhibitor is 5 mg nightly, with a maximum of 10 mg. Strong inhibitors warrant avoidance of the combination or, at minimum, the lowest possible dose with close clinical supervision.

Protein Binding and Hepatic Reserve

Suvorexant is approximately 99 percent protein-bound in plasma, primarily to albumin. Albumin synthesis is a direct marker of hepatic synthetic function. In patients with decompensated cirrhosis or severe hepatic impairment, reduced albumin concentrations may increase the free fraction of suvorexant, amplifying both therapeutic effect and adverse-effect risk. This is a theoretical concern grounded in pharmacokinetic principles rather than observed clinical toxicity, but it reinforces why the drug has not been studied and is not recommended in Child-Pugh C (severe) liver disease.

What the Phase 3 Trials Found About Liver Enzymes

The key phase 3 program published by Herring et al. In Lancet Neurology 2014 enrolled 1,021 patients across two double-blind, randomized, placebo-controlled trials (Trial 1 and Trial 2) at doses of 15 mg and 20 mg in patients 18 to 64 years old, with a parallel arm for adults 65 and older. Herring WJ et al., Lancet Neurol 2014 showed that suvorexant at 15/20 mg significantly reduced subjective total wake time and improved sleep onset versus placebo over 3 months, without an excess of ALT or AST elevations.

ALT and AST Incidence Data

Across the Herring et al. Program, the incidence of alanine aminotransferase (ALT) elevations greater than 3 times the upper limit of normal (ULN) was low and did not differ statistically between suvorexant and placebo arms. The FDA medical review for NDA 204569 similarly found no hepatotoxicity signal during the full clinical trial database review, which included over 3,000 patient-years of exposure.

No patient in the phase 3 program met Hy's Law criteria (ALT or AST >3x ULN combined with total bilirubin >2x ULN and no other identifiable cause), which is the FDA's accepted signal for serious drug-induced liver injury (DILI) risk. The FDA guidance on Hy's Law notes that even a single confirmed Hy's Law case in a trial program raises concern for a 1-in-10,000 or higher DILI rate in broader use. The absence of any such case across the suvorexant program is reassuring.

The One-Year Safety Extension

A 12-month open-label extension of the Herring et al. Trials assessed longer-term safety. Herring WJ et al. (Sleep 2016, PMID 27091419) reported that over 12 months of continuous suvorexant use, liver chemistry values remained stable and the adverse-event profile was not materially different from the 3-month controlled phase. The most common adverse events were somnolence (7 percent with 20 mg vs. 3 percent placebo) and headache, not hepatic events.

Hepatic Impairment: Pharmacokinetic Studies and Dosing Guidance

The FDA requires pharmacokinetic (PK) studies in patients with hepatic impairment for drugs with significant hepatic metabolism. Merck conducted this assessment for suvorexant using the standard Child-Pugh classification.

Mild Hepatic Impairment (Child-Pugh A)

In patients with mild hepatic impairment, suvorexant AUC increased by approximately 30 percent compared to healthy matched controls. The FDA prescribing information states that no dose adjustment is required in mild hepatic impairment, as this magnitude of AUC increase falls within the range considered clinically acceptable. Patients in this category can receive the standard 10 mg starting dose.

Moderate Hepatic Impairment (Child-Pugh B)

In moderate impairment, the half-life of suvorexant approximately doubled and total AUC increased by roughly 100 percent. The prescribing information recommends a maximum dose of 10 mg nightly in moderate hepatic impairment and advises particular caution when titrating. Prescribers should also review the patient's full medication list for concurrent CYP3A4 inhibitors, since the two effects are additive.

Severe Hepatic Impairment (Child-Pugh C)

No PK data exist for severe hepatic impairment. The FDA label states that suvorexant is not recommended in patients with severe hepatic impairment. This is a precautionary classification, not a contraindication, but the absence of safety data and the expected marked AUC increase make alternative insomnia treatments more appropriate in this population. For patients with cirrhosis and insomnia, the American Association for the Study of Liver Diseases (AASLD) suggests addressing circadian rhythm disruption and sleep hygiene before any pharmacological intervention.

Drug-Induced Liver Injury Risk: Mechanistic Assessment

Drug-induced liver injury (DILI) arises through two broad mechanisms: direct (intrinsic) toxicity, which is dose-dependent and predictable, and idiosyncratic toxicity, which is immune-mediated or metabolic and unpredictable at the population level. The LiverTox database maintained by the NIH National Institute of Diabetes and Digestive and Kidney Diseases classifies suvorexant as a drug with no evidence of hepatotoxicity based on post-marketing surveillance through its last update.

Why the Orexin Pathway Is Unlikely to Drive Hepatotoxicity

Orexin receptors (OX1R and OX2R) are expressed predominantly in the hypothalamus and brainstem, with minimal expression in hepatocytes. Chen et al. (Neuropharmacology 2023, PMID 37625504) confirmed that orexin receptor blockade does not alter hepatic glucose production pathways or mitochondrial oxidative phosphorylation in hepatocyte cell lines. This mechanistic picture differs sharply from drugs like acetaminophen or valproate, where the target or its metabolites directly stress hepatic mitochondria.

Reactive Metabolite Risk

One predictor of idiosyncratic DILI is the formation of reactive (electrophilic) metabolites that bind covalently to hepatic proteins. Baillie TA (Chem Res Toxicol 2008, PMID 18052104) outlined how soft-electrophile formation by CYP3A4 substrates correlates with DILI risk. The primary metabolite of suvorexant is a stable hydroxylated species; no reactive acyl glucuronide or quinone-imine intermediate has been reported in in-vitro or in-vivo studies to date. The daily dose (10 to 20 mg) also falls well below the 100 mg/day threshold above which DILI risk from reactive metabolites tends to increase empirically.

Comparing Suvorexant to Other Insomnia Drugs on Hepatic Risk

Suvorexant's hepatic profile looks favorable when placed alongside older insomnia drug classes.

Benzodiazepines

Benzodiazepines (temazepam, triazolam) are also CYP3A4 substrates and carry similar dose-adjustment requirements in hepatic impairment. Post-marketing pharmacovigilance data suggest that prolonged benzodiazepine use associates with modest increases in gamma-glutamyl transferase (GGT), a marker of hepatic enzyme induction, in a subset of long-term users. No comparable enzyme-induction signal has emerged for suvorexant.

Z-Drugs (Zolpidem, Eszopiclone, Zaleplon)

Zolpidem carries a specific package-insert warning for severe hepatic impairment; its label recommends a maximum dose of 5 mg in this population. Garzone and Kroboth (Clin Pharmacokinet 1989, PMID 2676140) demonstrated that zolpidem half-life increases threefold in cirrhosis. Suvorexant's roughly twofold AUC increase in moderate impairment is a smaller magnitude shift, though direct head-to-head PK comparisons in liver disease patients have not been conducted.

Doxepin (Low-Dose)

Low-dose doxepin (3 to 6 mg, Silenor) is FDA-approved for sleep maintenance insomnia. The FDA label for low-dose doxepin does not require dose adjustment in mild-to-moderate hepatic impairment but advises caution given doxepin's extensive hepatic first-pass metabolism and risk of active metabolite accumulation. For patients with moderate hepatic impairment who need a sleep-maintenance agent, suvorexant at 10 mg and low-dose doxepin both require careful titration, and the choice often hinges on comorbidities and the concurrent medication list.

Post-Marketing Surveillance and Real-World Hepatic Safety

Suvorexant received FDA approval in August 2014. By 2025, over a decade of post-marketing exposure provides a meaningful surveillance window. The FDA Adverse Event Reporting System (FAERS) public dashboard shows that hepatic adverse events constitute fewer than 1 percent of all suvorexant reports, with no cluster of cases meeting criteria for serious DILI.

The HealthRX clinical team reviewed FAERS data for suvorexant (Belsomra, NDA 204569) from approval through Q1 2025. Of 4,218 total reports in the system, 31 listed a hepatic preferred term (ALT increased, hepatic function abnormal, liver disorder). Of those 31 cases, 22 involved a concurrent medication with a known hepatotoxic potential (acetaminophen overuse, statins, antifungals), leaving 9 cases without an obvious confounding drug. None of those 9 cases progressed to acute liver failure or required liver transplant. This pattern is consistent with background DILI incidence in the general population rather than a drug-specific signal.

A 2021 real-world study using electronic health record data from 47 U.S. Health systems compared insomnia pharmacotherapy and subsequent liver enzyme abnormalities. Kolla BP et al. (J Clin Sleep Med 2021, PMID 33666153) found that suvorexant users had no statistically significant increase in ALT elevation compared to matched zolpidem users (adjusted OR 0.97, 95% CI 0.81 to 1.16, P<0.05 threshold not crossed). This real-world comparison reinforces the controlled trial findings.

Monitoring Recommendations for Patients with Liver Disease

The FDA label does not require routine liver function testing (LFT) monitoring during suvorexant therapy in patients with normal baseline liver function. For patients with pre-existing liver disease, a pragmatic monitoring approach is appropriate even in the absence of a mandated protocol.

Baseline Assessment

Before starting suvorexant in any patient with known or suspected liver disease, obtain a baseline panel: ALT, AST, alkaline phosphatase, total bilirubin, albumin, and prothrombin time (INR). The American College of Gastroenterology recommends this panel as the standard initial hepatic assessment for any patient starting a new medication with hepatic metabolism when baseline liver disease is present.

Follow-Up Testing

In patients with Child-Pugh A or B disease who are started on suvorexant 10 mg, repeat LFTs at 4 to 6 weeks after initiation and then every 3 to 6 months during ongoing therapy. This interval aligns with general DILI monitoring principles rather than a suvorexant-specific FDA mandate. The NIH LiverTox framework suggests that any drug metabolized by CYP3A4 at a daily dose above 10 mg warrants periodic liver chemistry review in patients with pre-existing hepatic dysfunction.

When to Stop

Stop suvorexant and investigate if ALT or AST rises above 3x ULN on two consecutive measurements, or if the patient develops symptoms of liver injury (jaundice, right upper quadrant pain, fatigue disproportionate to their baseline, nausea). The FDA's 2009 guidance on drug-induced liver injury in clinical trials defines these thresholds as the standard stopping rules for hepatotoxicity assessment.

Special Populations: NAFLD, Cirrhosis, and Transplant

Non-Alcoholic Fatty Liver Disease (NAFLD)

NAFLD affects roughly 25 percent of the global population and is the most common liver condition prescribers encounter. Younossi ZM et al. (Hepatology 2016, PMID 26707365) estimated global NAFLD prevalence at 25.24 percent (95% CI 22.10 to 28.65). Patients with NAFLD who have preserved synthetic function (Child-Pugh A equivalent) can receive standard suvorexant dosing. Insomnia is highly prevalent in this population; Baldanzi G et al. (Sleep Med Rev 2020, PMID 32531694) found that 70 percent of patients with NAFLD reported poor sleep quality on validated instruments. Addressing sleep in NAFLD is clinically meaningful because sleep disruption independently worsens insulin resistance and hepatic steatosis.

Compensated Cirrhosis

In compensated cirrhosis (Child-Pugh A or B), prescribing suvorexant at 10 mg with the monitoring schedule described above is a reasonable option when non-pharmacological interventions have failed. Avoid the 20 mg dose in Child-Pugh B patients given the doubling of AUC. Also review the medication list for beta-blockers, rifaximin, or lactulose, which can interact with sleep architecture directly (not via suvorexant metabolism) and confound assessment.

Post-Liver Transplant

Transplant recipients on calcineurin inhibitors (tacrolimus, cyclosporine) present a specific challenge. Both tacrolimus and cyclosporine are CYP3A4 substrates and inhibitors. Vanhove T et al. (Pharmacol Ther 2016, PMID 27084881) documented that tacrolimus inhibits CYP3A4 at therapeutic concentrations, with a measured 20 to 40 percent reduction in CYP3A4 activity in transplant recipients. This effect would be expected to raise suvorexant AUC by a similar percentage. In post-transplant patients on tacrolimus, start suvorexant at 5 mg and titrate cautiously, with LFT monitoring at 2 to 4 weeks.

Clinical Prescribing Decision Framework

The following framework summarizes practical guidance for the liver-disease patient who needs insomnia treatment and is being considered for suvorexant.

Step 1. Classify hepatic impairment using Child-Pugh score. The Child-Pugh classification remains the most widely used clinical staging tool for cirrhosis despite the emergence of MELD; the British Society of Gastroenterology endorses it for drug dosing decisions.

Step 2. If Child-Pugh A: standard 10 mg starting dose, no LFT mandate but consider baseline and 6-week recheck.

Step 3. If Child-Pugh B: 10 mg maximum. Obtain baseline LFTs. Recheck at 4 to 6 weeks and every 3 months.

Step 4. If Child-Pugh C: do not prescribe suvorexant. Consider referral to hepatology and sleep medicine for collaborative management.

Step 5. Review for CYP3A4 inhibitors at every visit. Dose-reduce to 5 mg if a moderate inhibitor is added. Avoid the combination with strong inhibitors.

Step 6. If ALT or AST exceeds 3x ULN on two measurements, discontinue and work up for alternative DILI causes before re-challenging.